About Us

Image-about us
Generated with Avocode. Rectangle

Our Vision

NETRIS Pharma is dedicated to provide novel therapeutic solutions to patients suffering from cancer. We focus on innovative drugs that effectively restore cancer cell death, limit cancer cell plasticity, and alleviate resistance to current antiproliferative treatments such as chemotherapy, targeted therapy and immunotherapy. The company leverages its unique understanding of the mode-of-action of Netrin-1 and its receptor UNC5H.

Hitachi and Centre Léon Bérard cancer center in Lyon to launch a research collaboration in the fight against cancer with AI

At the Core of Clinical Excellence

The company is located in Lyon (France) within the Léon Bérard Comprehensive Cancer Center. First spin-off of the Center, the Company benefits from a unique research and clinical environment for its development. NETRIS Pharma is Partner of several “Investissements d’Avenir” programs such as the “Laboratory of excellence” DEVweCAN, the Convergence Institute PLASCAN, the RHU DepGyn and the EIC Accelerator. The Company also internationally collaborates with  world-renowned Institutions, Pharmaceutical and industrial Companies.

Our Impact

NETRIS Pharma is focused on delivering superior clinical benefit to patients not responding well to anti-proliferative therapies. NETRIS Pharma is providing safer treatments to patients by developing new drugs targeting moieties, that are only expressed by the tumor. NETRIS Pharma organizes or strongly contributes  to scientific conferences dedicated to cancer cell resistance mecanisms and actively welcome motivated PhD scientist.


Our Team

Our team combines complementary experience in fundamental and translational research, clinical development and corporate developments.


Get in touch

Contact us